Rabbit Anti-Mouse Lyve-1
Slide this table
| Cat-Nr. | 103-PABi50 |
| Size | 50 µg |
| Price | 275 € |
| Category | Polyclonal Antibody |
| Label | Biotin |
| Clone Nr. | Rabbit IgG |
| Species Reactivity | Mouse |
| Formulation | lyophilized |
| Buffer | PBS |
| Stabilizer/Carrier | BSA (50x), 0.02% sodium azide |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
| Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
| Preparation | Produced from sera of rabbits immunised with highly pure recombinant mouse soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis). The antibody was purified via an antigen-affinity column and then biotinylated using a standard protocol. LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE 1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves. |
| Antigen | Recombinant mouse soluble LYVE-1 (RT #S01-026) |
| Application | FC |
| Synonyms | Lyve1; Xlkd1; Lyve-1; Crsbp-1; 1200012G08Rik |
| Description | LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves. |
| Uniprot ID | Q8BHC0 |
| Protein RefSeq | NP_444477 |
| mRNA RefSeq | NM_053247 |
Figures
Functional ELISA with anti-mouse LYVE-1 [Cat# 103-PABi50]. Recombinant mouse soluble LYVE-1 [Cat# S01-026] was coated with increasing amounts in a 96 well microtiter plate.
Reference
- Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF‐C/VEGFR-3 signalling pathway. M. García‐Caballero et al., Br J Pharmacol. 2016 Jun; 173(12): 1966–1987.
All prices plus VAT + possible delivery charges